← All trials
NCT03294954
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2018
- Primary completion
- Sep 10, 2019
- Completion date
- Aug 10, 2034
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Baylor UniversityLead sponsor
- Baylor UniversityReponsible party - principal investigator
- Baylor UniversityOverall official - principal investigator
- Baylor UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.